CLP-3094

CLP-3094 is a potent BF3 (binding function 3) -directed inhibitor of the androgen receptor (AR) . CLP-3094 inhibits AR transcriptional activity (IC50=4 μM) [1]. CLP-3094 is a selective, potent GPR142 antagonist[2].

Product Specifications

CAS Number

[312749-73-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/clp-3094.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(OCCSC2=NC3=CC=CC=C3N2)C=C1

Molecular Formula

C15H13ClN2OS

Molecular Weight

304.79

Precautions

H302, H315, H319, H335

References & Citations

[1]Munuganti RS, et al. Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2- ((2-phenoxyethyl) thio) -1H-benzimidazole derivatives. J Med Chem. 2013;56 (3) :1136-1148.|[2]Murakoshi M, et al. Discovery and pharmacological effects of a novel GPR142 antagonist. J Recept Signal Transduct Res. 2017;37 (3) :290-296.